🇺🇸 FDA
Pipeline program

Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

LP0162-1336

Phase 3 small_molecule active

Quick answer

Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP. for Treatment of moderate-to-severe Atopic dermatitis is a Phase 3 program (small_molecule) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
LEO Pharma A/S
Indication
Treatment of moderate-to-severe Atopic dermatitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials